Highest investment in the sector in last 5 years; pandemic expands opportunities
The drug is indicated for the prevention of excessive bleeding in women after vaginal or caesarean childbirth
it is likely many states would have under-reported data on mortality rates, while misreporting on other key aspects concerning their health sector as well
Throw in the financial consequences and you know that your loved ones will be under tremendous pressure if they have to make this decision
Maharashtra Deputy Chief Minister Ajit Pawar said it deliberated on tax relief on medicines, injections and health equipment
The healthcare sector is in the limelight for the second consecutive year
States have been asked to prepare and implement the infection prevention control programme in hospitals in accordance with the National Guidelines for Infection and Control in Healthcare Facilities
India has a huge diabetic population that is at risk. And along with that, steroids and antibiotics are being used quite irrationally for Covid-19 patients
Company says it has trained over 5,500 people since the pandemic started last year.
Consumer goods firm Godrej & Boyce is looking at double-digit growth in its healthcare business going forward, and after the pandemic started in March 2020, it has witnessed a sustained rising demand of its key healthcare products and solutions, said a top company official. Besides, Godrej & Boyce, part of over USD 4.1-billion Godrej Group and a leading maker of medical refrigerators in India, is also quite open to alliance with any vaccine makers such as Pfizer's, that needs to be kept in (-) 70 degrees Celsius. The company's healthcare businesses are growing in the range of 22-25 per cent in the past year, said Godrej & Boyce Executive Director Nyrika Holkar. Godrej & Boyce is operating in the healthcare sector through its multiple step-down subsidiaries, which include Godrej Appliances, Godrej Interio and Godrej Lawkim, in areas such as hospital beds, medical refrigerators and calibration services for medical equipment like ventilators. "We believe that the ...
Avoid over 5% exposure and have 5-7 years of investment horizon
Drug firm Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for Lurasidone Hydrochloride tablets, used to treat bipolar depression. The approved product is therapeutically equivalent to the reference listed drug product (RLD) Latuda tablets of Sunovion Pharmaceuticals Inc. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Lurasidone Hydrochloride tablets in the strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, Alembic Pharmaceuticals said in a regulatory filing. Quoting IQVIA data, Alembic Pharma said Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg have an estimated market size of USD 3.7 billion for the twelve months ending December 2020. Lurasidone Hydrochloride tablets are indicated for treatment of major depressive episodes associated with bipolar I disorder (bipolar depression). Alembic Pharma said it has settled the cas
Consolidated total income up 13%; robust anti-diabetic sales, new product pipeline, expanded coverage of cardiologists support better numbers
The deal is to sell one of Cadila's two businesses on a slump sale basis as a going concern, for a lump sum of Rs 2,921 cr on cash-free and debt-free basis
With Telangana's healthcare sector grappling with mounting pressure of Covid pandemic, Chief Minister K Chandrasekhar Rao has decided to temporarily draw upon fresh medical and paramedical graduates
Availability of funds due to recent measures announced by the Reserve Bank of India (RBI) can result in increased capacities: ICRA
Centre's support and private sector participation may relieve some of the load
Central govt should not leave everything to states
In the domestic market, growth is expected to come from Covid-related drugs
The injection is used for short-term intravenous treatment of patients with acute decompensated heart failure